The Proviron underground

A real drug with a real past

Start with the part that is not folklore. Mesterolone was described in 1966 and introduced by Schering in 1967 under a brand name the company had used since the 1930s for testosterone propionate. It was approved in Germany, the UK, Australia, South Africa, and much of the rest of the world as an oral androgen for male hypogonadism, and it was used for years as an adjunct in idiopathic male infertility on the theory that a mild, non-suppressive androgen might nudge sperm quality. It was never approved in the United States, Canada, or New Zealand, and it still isn't.

So this is not a research chemical or a designer steroid. It is a legacy European prescription drug with a half-century of pharmacology on file. That matters, because it is exactly what makes the online story credible enough to survive: the compound is real, the receptor logic is real, and only the claim on top of it is unproven.

The pharmacology, plainly

Chemically, mesterolone is 1-alpha-methyl-dihydrotestosterone: DHT with a single methyl group added at the 1 position. That small change is what lets it survive a trip through the liver by mouth without the 17-alpha-alkylation that makes most oral anabolic steroids hepatotoxic. Because it is already a 5-alpha-reduced molecule, it cannot aromatize to estrogen. It is a weak anabolic (nobody builds muscle on it) with DHT-like activity at the androgen receptor, and it binds sex hormone-binding globulin (SHBG) with unusually high affinity.

Four properties, then: oral, non-aromatizing, weak anabolic, strong SHBG binder. Hold onto them, because every claim the forums make about Proviron is an inference from one of those four.

How it became folklore

The Proviron story did not start in men's sexual health. It started on bodybuilding boards in the early 2000s, where the drug was a cycle accessory: cheap, mild, oral, and reputed to keep libido up while other compounds were suppressing it. The recurring line was that it made everything else "work better" and that erections got harder while it was in the stack. The "on-cycle libido" reputation was the seed. When those same men aged into testosterone therapy and into forums about erectile function, the reputation came with them.

Three arguments carried it, and each one is a real mechanism pushed past what the evidence can hold.

Notice the shape of all three. A verifiable property of the molecule, a plausible mechanism, and then a jump to "better erections" that no one measured. That jump is the whole underground.

What the trials actually say

Mesterolone was tested, in its era, for two things: hypogonadal symptoms and male infertility. Neither test went the way the folklore would predict.

Hypogonadism. The clearest head-to-head is a small 1980 double-blind trial from Pisa comparing oral testosterone undecanoate with mesterolone in hypogonadal men, scoring sexual activity and mood. Testosterone won, and not narrowly: after four weeks, libido, erections, ejaculation, and mental state were all significantly better on testosterone than on mesterolone. In men who were actually androgen-deficient, the DHT derivative was the weaker replacement. There is a 2014 report from Turkey in which 34 men with aging-male symptoms took mesterolone for two months and scored better on symptom questionnaires, but it had no placebo arm and no control group, which puts it in the same evidence tier as the forums it is quoted on.

Infertility. This is where the drug got its biggest fair trial. In 1989 the World Health Organization's infertility task force ran a seven-centre, randomized, double-blind, placebo-controlled study of six months of mesterolone in 248 couples with idiopathic male-factor infertility. Pregnancy rates were 9% on placebo and 12% and 16% on the two mesterolone arms, with confidence intervals that comfortably included no effect, and semen quality did not differ between groups. A 1991 Belgian placebo-controlled trial found the same thing over twelve months: sperm motility and morphology improved on the drug, but they also improved on placebo, and the pregnancy rate was numerically lower in the treated group. The Cochrane review that pooled eleven androgen trials in 930 men concluded there was no evidence of benefit. The infertility indication faded on its evidence.

Erectile function. Here the record is simply empty. There is no randomized trial of mesterolone for erectile dysfunction, none for erection quality in eugonadal men, and none in men already on testosterone therapy, which is the exact population the modern folklore targets. The drug has been legally available in Europe for nearly sixty years and nobody has run the study, which tells you how the people who could run it rate the prior.

The closest real experiment: DHT gel

If you want to know what a DHT-axis androgen does to sexual function in older men when someone actually measures it, you don't need Proviron trials. Transdermal DHT gel has been through several placebo-controlled studies, and it is the same lever: a non-aromatizing androgen with DHT's receptor profile.

The best-known is the Finnish trial by Kunelius and colleagues, published in 2002: 120 men aged 50 to 70 with andropause symptoms, infrequent nocturnal erections, and low-normal testosterone or high SHBG, randomized to six months of DHT gel or placebo. The DHT group reported a transient improvement in early-morning erections at three months and a modest improvement in the ability to maintain an erection. General well-being did not differ from placebo. Lipids and prostate measures were unchanged, hematocrit rose, and, this is the part to hold onto, testosterone, LH, FSH, and estradiol all fell significantly. The DHT replaced the man's own axis rather than adding to it.

Then the Sydney group ran the long one: 114 healthy men over 50 on daily DHT gel or placebo for two full years, with 33 measures of sexual function and mood tracked throughout. DHT completely suppressed native testosterone and estradiol for the duration. The result on sexual function was nothing: no effect on any measure, except a small, reversible decrease in overall sexual desire. Spinal bone density fell, because estrogen protects bone in men and this androgen makes none.

Read those two trials together and the picture of a DHT-axis androgen is clear. In androgen-deficient men, a little transient benefit on erections. In healthy men, no benefit, a slight cost to desire, a suppressed axis, and a bone signal. That is the honest expectation for the class mesterolone belongs to, and it is a long way from the forum version.

The risk ledger

Because mesterolone is mild and non-hepatotoxic, it acquired a reputation as the "safe" androgen. Mild is not the same as free, and the bill arrives in five places.

Suppression. Every exogenous androgen, including a weak one, feeds back on the hypothalamus and pituitary. The DHT gel trials above show the class effect in full: testosterone, LH, and FSH fall. For a man not on testosterone therapy, that means trading some of his own production for a weaker substitute. For a man trying to conceive, it means the WHO trial's null result is the good outcome; see testosterone and fertility for why any androgen and sperm production are in tension.

Hair and skin. This is a DHT molecule. Acne, body hair, and acceleration of male-pattern hair loss in men carrying the susceptibility are the documented androgenic effects, and hair loss from a DHT-axis drug does not reliably reverse.

Lipids and blood. Oral androgens as a class push HDL down. The transdermal DHT trials, interestingly, did not move lipids, but they did raise hemoglobin and hematocrit, and in the two-year study several men were withdrawn for hematocrit above the safety line. That is the same hematocrit problem testosterone therapy has to monitor for, arriving unmonitored.

Prostate. The DHT gel trials were reassuring on prostate volume and PSA, and the endocrinology reviews argue that circulating DHT and intraprostatic DHT are largely decoupled. That is genuinely good news for the class. It is also a finding from screened, monitored trial populations, and a man with an unknown prostate taking an unmonitored androgen is not in that population.

Identity and purity. This is the risk that dwarfs the others, because it is not pharmacological. With no US channel, "Proviron" sold to an American buyer is whatever the underground lab or reseller put in the blister. Underdosed, mislabeled, or substituted product is the norm in unregulated androgen markets, and a substituted 17-alkylated oral would carry exactly the liver risk mesterolone is praised for lacking. The product-forms literacy applies here in full: no licensed pharmacy, no certificate worth the name, no way to know.

The legal reality

In the United States, mesterolone is listed by name in the federal definition of "anabolic steroid" at 21 U.S.C. 802(41), which makes it a Schedule III controlled substance under the Anabolic Steroids Control Act. Possession without a valid prescription is a federal offense, and since the drug is not FDA-approved, there is no US prescription to be had; a compounding pharmacy cannot lawfully make it either. That is different from compounded trimix or an off-label bremelanotide script, and the difference is the whole point of our drug-tier guardrail: for this compound, no legitimate channel exists, so we build no path to one.

The honest bridge

Strip the folklore down and what remains is a real question wearing a gray-market answer. The men who swear by Proviron are almost always describing one of two things: low desire and soft erections with androgen levels they have never had properly measured, or a testosterone protocol that is not quite dialed in. Both are lab questions, and both are answerable inside the legal channel by someone qualified to read the result.

The SHBG argument, in particular, is a good argument for a blood test, not for a drug. If you suspect high SHBG is hiding a low free fraction, that is a hypothesis a morning total testosterone, SHBG, and albumin can confirm or kill. Run the numbers through the free testosterone calculator, learn to read the panel, and take it to a clinician. If the free fraction is genuinely low, that is what supervised testosterone therapy exists for, with the monitoring the risk ledger above demands. If it is not, the problem is somewhere else in the workup, and no androgen was going to fix it.

We are bullish on androgen physiology. The receptor biology the forums reasoned from is real, and the DHT gel trials are a genuinely interesting piece of endocrinology. We are sceptical of the page: a sixty-year-old drug with two failed indications, an empty record on erectile function, and a class comparator that shows no benefit in healthy men. When the mechanism is that good and the trial has still never been run, the smart move is to measure your own numbers first.

The bottom line

Mesterolone is a real legacy androgen with well-understood pharmacology: oral, non-aromatizing, weakly anabolic, and a strong SHBG binder. Its two approved-era indications tested weak or null. Its erectile-function reputation rests entirely on first-person reports, and the closest controlled evidence for its class, the DHT gel trials, shows at most a transient effect in androgen-deficient men and nothing in healthy ones. In the US it is Schedule III with no legal supply. If the signal it points to is yours, low desire or erection quality that PDE5 inhibitors don't address, the move that actually pays is a lab draw and a clinician who can read it. The underground had the question right. It just never had the answer.

Common questions